RLAY Relay Therapeutics Inc

Price (delayed)

$34.11

Market cap

$3.16B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.05

Enterprise value

$2.92B

Relay Therapeutics, Inc. operates as a biotechnology company. The Company develops durgs for the treatment of cancer. Relay Therapeutics serves customers in the United States.

Highlights
The EPS has surged by 96% year-on-year and by 79% since the previous quarter
The debt has contracted by 2.2% YoY
RLAY's quick ratio is down by 41% since the previous quarter but it is up by 8% year-on-year
Relay Therapeutics's net income has shrunk by 148% YoY
The equity has declined by 16% since the previous quarter

Key stats

What are the main financial stats of RLAY
Market
Shares outstanding
92.7M
Market cap
$3.16B
Enterprise value
$2.92B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.09
Price to sales (P/S)
37.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
34.61
Earnings
Revenue
$84.45M
EBIT
-$236.39M
EBITDA
-$232.68M
Free cash flow
-$42.16M
Per share
EPS
-$1.05
Free cash flow per share
-$0.46
Book value per share
$6.7
Revenue per share
$0.92
TBVPS
$7.75
Balance sheet
Total assets
$714.4M
Total liabilities
$95.87M
Debt
$23.72M
Equity
$618.53M
Working capital
$655.89M
Liquidity
Debt to equity
0.04
Current ratio
26.84
Quick ratio
26.55
Net debt/EBITDA
1.03
Margins
EBITDA margin
-275.5%
Gross margin
100%
Net margin
-279.9%
Operating margin
-281.4%
Efficiency
Return on assets
-54.5%
Return on equity
-58.6%
Return on invested capital
-62%
Return on capital employed
-34.3%
Return on sales
-279.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RLAY stock price

How has the Relay Therapeutics stock price performed over time
Intraday
-6.85%
1 week
21.13%
1 month
-7.64%
1 year
-9.09%
YTD
-17.93%
QTD
8.18%

Financial performance

How have Relay Therapeutics's revenue and profit performed over time
Revenue
$84.45M
Gross profit
$84.45M
Operating income
-$237.6M
Net income
-$236.39M
Gross margin
100%
Net margin
-279.9%
Relay Therapeutics's net income has shrunk by 148% YoY
RLAY's operating income has dropped by 133% year-on-year

Growth

What is Relay Therapeutics's growth rate over time

Valuation

What is Relay Therapeutics stock price valuation
P/E
N/A
P/B
5.09
P/S
37.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
34.61
The EPS has surged by 96% year-on-year and by 79% since the previous quarter
The equity has declined by 16% since the previous quarter

Efficiency

How efficient is Relay Therapeutics business performance
The return on invested capital has dropped by 188% since the previous quarter and by 44% year-on-year
The ROA has shrunk by 99% YoY and by 47% QoQ
The company's return on equity fell by 17% QoQ

Dividends

What is RLAY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RLAY.

Financial health

How did Relay Therapeutics financials performed over time
Relay Therapeutics's total liabilities has soared by 169% YoY and by 149% from the previous quarter
RLAY's total assets has soared by 105% YoY but it is down by 7% QoQ
The debt is 96% less than the equity
Relay Therapeutics's debt to equity has soared by 136% YoY and by 33% from the previous quarter
The equity has declined by 16% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.